Peer-Reviewed Publications Demonstrate Tethys Bioscience, Inc.'s Ability to Identify Those at Highest Risk of Developing Type 2 Diabetes Within Five Years

EMERYVILLE, Calif.--(BUSINESS WIRE)--As diabetes reaches epidemic proportions in the United States, clinicians struggle with a difficult question: how to prioritize their efforts to prevent the progression to diabetes in a population where more than 57 million Americans are currently estimated to be at risk for type 2 diabetes.